{'fraction_non_alphanumeric': 0.02474793767186068, 'fraction_numerical': 0.002749770852428964, 'mean_word_length': 4.967213114754099, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Changes in the levels of human platelet membrane glycoproteins in patients with a new-type defect of platelet aggregation].

Labeled avidin-biotin (LAB)-enzyme linked immunosorbent assay (ELISA) for quantitative measurement of the levels of human platelet membrane glycoproteins (GPs) Ib, IIb and IIIa was developed by using a group of murine monoclonal antibodies raised against human platelet membrane GPs. The contents of the GPs Ib, IIb and IIIa in patients with a new-type defect of platelet aggregation were detected and found to be in normal range. However, the amounts of GPs IIb and IIIa before washing in patients were significantly decreased in these patients when compared with those in controls (P less than 0.01), while after washing, normal levels could be obtained. The results reported have support the hypothesis that the pathogenesis of this defect in platelet aggregation seems not to be associated with the abnormality of the levels of GPs, but is a result of abnormal factor existing in the plasma. Further investigation on the properties of the factor is in progress.